New Strategies for a Comprehensive Fight Against HIV Infection using Monoclonal Antibody Therapy.

Abstract

Highly active antiretroviral therapy (ART) has allowed a long-term control of viral replication and HIV infection has been transformed into a chronic disease. However, ART is not able to eradicate the virus, and high levels of inflammation and immune-activation are observed despite prolonged ART. Consequently, a number of comorbidities, such as cardiovascular diseases and cancer, are gaining relevance in patients living with HIV. Moreover, the toxicities associated with continued exposure to ART cause several metabolic disturbances with clinical relevance, and the cost of treatment is a heavy burden for the national health systems. In this scenario, new therapeutic strategies aiming at viral eradication are being actively pursued.

• Authors: Eva Poveda, Manuel Crespo
• Journal: AIDS reviews (AIDS Rev) 2016 Jul - Sep Vol. 18 Issue 3 Pg. 166 ISSN: 1698-6997 [Electronic] Spain
• PMID: 27721508 (Publication Type: Journal Article, Review)

Chemical References

• 3BNC117 antibody
• Anti-HIV Agents
• Antibodies, Monoclonal, Humanized
• Antibodies, Neutralizing
• Broadly Neutralizing Antibodies
• HIV Antibodies

Topics

• Anti-HIV Agents (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antibodies, Neutralizing (therapeutic use)
• Antiretroviral Therapy, Highly Active
• Broadly Neutralizing Antibodies
• HIV Antibodies (therapeutic use)
• HIV Infections (therapy)
• Humans